A new ADHD drug hits three brain chemicals — is it coming here?

What just happened

A new ADHD medication called centanafadine — brand name Simtriyo — has received approval from the US Food and Drug Administration for adults and children aged six and over. Researchers from Adelaide University writing in The Conversation this week describe it as “the first [ADHD treatment] to affect three brain chemicals: noradrenaline, dopamine and serotonin” — a meaningful distinction from every currently available ADHD medication.

Centanafadine is not available in Australia. It has not been assessed by the TGA. But the mechanism it uses matters independently of the regulatory timeline, and it speaks directly to something that a large number of Australians with ADHD have been asking for years: a treatment that might also help with the anxiety and depression that so frequently sit alongside an ADHD diagnosis.

This is not a “treatment is coming” announcement. It is a “here is what the science is doing, and why it matters to watch” signal.

Both-and

What makes centanafadine different

All current ADHD medications available in Australia — methylphenidate (Ritalin, Concerta), lisdexamfetamine (Vyvanse), dexamfetamine, and atomoxetine — work primarily by increasing the availability of dopamine and noradrenaline in the brain. Some are stimulants; atomoxetine works differently but still targets the same two neurotransmitter systems.

Centanafadine slows the reuptake of a third neurotransmitter: serotonin. In practical terms, this means the drug keeps serotonin active in the brain for longer alongside dopamine and noradrenaline — a triple-reuptake inhibitor mechanism that is biologically distinct from anything currently PBS-listed for ADHD.

Serotonin is most associated with mood regulation and anxiety, which is why the Adelaide University researchers note that the serotonin activity “suggests potential benefits for patients with comorbid anxiety or depression, though this remains under investigation.” The word suggests is doing real work in that sentence. The mechanism is plausible; the clinical proof in head-to-head comparisons does not yet exist.

What the trials actually showed — and what they didn’t

Four phase-3 clinical trials demonstrated symptom improvement and acceptable tolerability. The drug works for ADHD symptoms. The side effect profile — appetite reduction, insomnia, dry mouth, headaches — is comparable to existing stimulant treatments. This is not a medication that appears to create new categories of harm.

But the trials compared centanafadine to placebo — not to the ADHD medications already available. This is a standard drug-approval methodology, and it is a meaningful limitation for anyone trying to understand whether centanafadine represents an improvement over what’s already on the market. The FDA approval confirms the drug is better than nothing. It does not confirm it is better than Vyvanse, Ritalin, or atomoxetine for any specific patient or presentation.

The serotonin hypothesis — that people with ADHD and comorbid anxiety or depression might benefit more from a triple-action mechanism — is one that researchers will likely pursue in the next round of evidence. For now, the answer to “is this better for people who have ADHD plus anxiety?” is genuinely: we do not know yet.

The Australian context: ADHD in women, and why the pipeline matters

ADHD has been systematically under-diagnosed in women and girls in Australia. Diagnostic criteria developed primarily on male populations, and the presentation in women often differs — more inattentive, less overtly hyperactive, more frequently masked by adaptive behaviour and internalised symptoms. Recognition of this has been growing in Australian general practice, but the backlog of adults — particularly women in their 30s and 40s — only recently identified and beginning the process of trialling medications is substantial.

For this population, the co-occurrence of anxiety and depression with ADHD is common and clinically significant. Many women who have been diagnosed with ADHD in mid-life have spent years in the mental health system being treated for anxiety or depression as primary conditions, while the ADHD that was driving or complicating both went unrecognised. The theoretical appeal of a mechanism that addresses all three neurotransmitter systems at once is obvious.

That theoretical appeal is why centanafadine is worth knowing about — even though the clinical evidence for superior benefit in comorbid presentations has not been established, and even though the drug is not available in Australia. The research direction matters because it reflects a genuine shift in how ADHD pharmacology is being approached.

A PBS listing in Australia would require a TGA application, evaluation, and PBAC assessment after that — a process that typically takes several years after FDA approval. There is no public indication that a TGA submission is underway.

My two cents

If you have ADHD and are on a medication that isn’t working well — particularly if anxiety or depression is part of your experience — the honest current answer is: centanafadine may eventually offer something different, but it will not be available here soon, and we do not yet have evidence that it outperforms what’s already listed on the PBS.

The more immediately useful question, if your current medication isn’t right, is whether you have had a structured review of your current treatment — dose, formulation, timing, and what the specific gaps are. The PBS-listed options vary considerably in their duration, mechanism, and tolerability, and many people find that a different existing medication addresses what the first one didn’t.

Centanafadine is genuinely interesting science. The triple mechanism is novel. The FDA approval is a first step. But for Australian patients, “watch this space” is the most accurate framing for the next two to three years at minimum.

Verdict: maybe — the mechanism is worth understanding now, even though the drug is years from Australian availability.

---

Sources cited

1. A new ADHD drug targets three brain chemicals instead of two. Jack Janetzki and Lisa Kalisch Ellett, Adelaide University. The Conversation, 12 August 2026. https://theconversation.com/a-new-adhd-drug-targets-three-brain-chemicals-instead-of-two-heres-what-that-means-288710
2. ADHD medications listed on the PBS. Australian Government Pharmaceutical Benefits Scheme. https://www.pbs.gov.au/browse/medicine-listing?q=ADHD&related-program=&product-manufacturer=&product-type=&show=pharmaceutical
3. Therapeutic Goods Administration — medicines for attention deficit hyperactivity disorder. https://www.tga.gov.au/resources/resource/guidance/medicines-adhd